Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer

Journal of Clinical Oncology

Volumn 18, Issue 8, 2000, Pages 1689-1695

  Schelling, M ^a   Avril, N ^a   Nahrig J ^a   Kuhn, W ^a   Romer W ^a   Sattler, D ^a   Werner, M ^a   Dose, J ^a   Janicke F ^a   Graeff, H ^a   Schwaiger, M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; PACLITAXEL;

ACCURACY; ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CLINICAL ARTICLE; HISTOPATHOLOGY; HUMAN; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0034001789     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.8.1689     Document Type: Article

References (34)

1. Attia-Sobol J, Ferriere JP, Cure H, et al: Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: Univariate and multivariate analysis. Eur J Cancer 8:1081-1088, 1993
2. Scholl SM, Fourquet A, Asselain B, et al: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial - S6. Eur J Cancer 5:645-652, 1994
3. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997
4. Mauriac L, Durand M, Avril A, et al: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm: Results of a randomized trial in a single centre. Ann Oncol 2:347-354, 1991
5. Bonadonna G, Valagussa P, Zucali R, et al: Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin 45:227-243, 1995
6. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
7. Machiavelli MR, Romero AO, Perez JE, et al: Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 4:125-131, 1998
8. Honkoop AH, van Diest PJ, de Jong JS, et al: Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 77:621-626, 1998
9. Chollet P, Charrier S, Brain E, et al: Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 33:862-866, 1997
10. Vinnicombe SJ, MacVicar AD, Guy RL, et al: Primary breast cancer: Mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology 198:333-340, 1996
11. Helvie MA, Joynt LK, Cody RL, et al: Locally advanced breast carcinoma: Accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. Radiology 198:327-332, 1996
12. Herrada J, Iyer RB, Atkinson EN, et ai: Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res 3:1565-1569, 1997
13. Abraham DC, Jones RC, Jones SE, et al: Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 78:91-100, 1996
14. Yang WT, Lam WW, Cheung H, et al: Sonographic, magnetic resonance imaging, and mammographic assessments of preoperative size of breast cancer. J Ultrasound Med 16:791-797, 1997
15. Warburg O: On the origin of cancer cells. Science 123:309-321, 1956
16. Gallagher BM, Fowler JS, Gutterson NI, et al: Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for the biodistribution of (18-F) 2-deoxy-2-fluoro-D-glucose. J Nucl Med 19:1154-1161, 1978
17. Rigo P, Paulus P, Kaschten BJ, et al: Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 23:1641-1674, 1996
18. Weber WA, Avril N, Schwaiger M: Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol 175:356-373, 1999
19. Wahl RL, Cody RL, Hutchins GD, et al: Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 179:765-770, 1991
20. Adler LP, Crowe JP, al-Kaisi NK, et al: Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 187:743-750, 1993
21. Avril N, Dose J, Jänicke F, et al: Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 14:1848-1857, 1996
22. Avril N, Dose J, Jänicke F, et al: Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 88:1204-1209, 1996
23. Moon DH, Maddahi J, Silverman DH, et al: Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 39:431-435, 1998
24. Wahl RL, Zasadny K, Helvie M, et al: Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 11:2101-2111, 1993
25. Jansson T, Westlin JE, Ahlstrom H, et al: Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation? J Clin Oncol 13:1470-1477, 1995
26. Bassa P, Kim EE, Inoue T, et al: Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 37:931-938, 1996
27. Dehdashti F, Flanagan FL, Mortimer JE, et al: Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 26:51-56, 1999
28. Hamacher K, Coenen HH, Stöcklin G: Efficient stereospecific synthesis of nocarrier-added 2-(F-18)-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27: 235-238, 1986
29. Avril N, Bense S, Ziegler SI, et al: Breast imaging with fluorine-18-FDG PET: Quantitative image analysis. J Nucl Med 38: 1186-1191, 1997
30. Sobin LH, Wittekind C (eds): TNM classification of malignant tumours (ed 5). New York, NY, Wiley, 1997
31. Som P, Atkins HL, Bandoypadhay D, et al: A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): Nontoxic tracer for rapid tumor detection. J Nucl Med 21:670-675, 1980
32. Higashi K, Anaira CC, Wahl RL: Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 34:414-419, 1993
33. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
34. McMasters KM, Hunt KK: Neoadjuvant chemotherapy, locally advanced breast cancer, and quality of life. J Clin Oncol 17:441-444, 1999 (editorial)